目的：观察精制去纤酶治疗脑梗塞的疗效，并探讨影响疗效的有关因素。方法：５０ 例病程在３～７２ ｈ 内脑梗塞静脉滴注精制去纤酶，首剂２ Ｂｕ，第３、５、７ ｄ 各用１ Ｂｕ；根据临床及实验室资料对其疗效进行多因素分析。结果：总有效率７８％ ，在２４ ｈ 内治疗的有效率为８１．９％ ，与２５～７２ ｈ 内治疗的疗效相比有显著性差异（ Ｐ＜ ０．０５），治疗后血纤维蛋白原、血浆粘度明显降低。多因素分析表明：疗效除与治疗时间有关外，还与病情程度、血糖水平有关，与年龄、性别、入院时血压、血脂水平等因素无关。结论：精制去纤酶治疗用于病情轻—中度，尤其是伴高纤维蛋白原血症的脑梗塞患者，应用越早，效果越明显。 Objective: To observe the curative effect of refined defibrase on cerebral infarction and to explore the relevant factors that affect curative effect. Methods: Fifty patients were treated by intravenous infusion of defibrase during the course of 50 ~ 72 h after intracerebral infarction. The first dose was 2 Bu, and the second, third and seventh day were 1 Bu respectively. According to the clinical and laboratory data, analysis. Results: The total effective rate was 78%, the effective rate of treatment within 24 hours was 81.9%, which was significantly different from the therapeutic effect within 25 ~ 72 hours (P <0.05). After treatment, the level of fibrin The original, plasma viscosity decreased significantly. Multivariate analysis showed that the effect was related to the severity of illness and blood glucose level except for the time of treatment, but not related to age, sex, blood pressure and blood lipid level at admission. CONCLUSIONS: Refined defibrase therapy is used in patients with mild to moderate disease, especially in patients with high-fibrinogenmia, and the earlier the application, the more pronounced the effect.